Clinical trial · Interventional
OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy
OV PRECISION: A Randomized Controlled Swiss Trial Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy in Ovarian Cancer.
NCT06466382CI-TRIAL-00110482OVPrecisionrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fallopian Tube Neoplasms | Fallopian Tube Neoplasm | ONTOLOGY_EXACT | 0.98 |
| High-grade Serous Ovarian Carcinoma (HGSOC) | — | UNRESOLVED | — |
| Ovarian Endometrioid Carcinoma | Ovarian Endometrioid Adenocarcinoma | ALIAS | 0.90 |
| Ovarian Neoplasm Epithelial | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin / Paclitaxel Chemotherapy | Drug | — | UNRESOLVED |
| Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Control Arm
- description
- Physicians and patients randomized to the SOC arm will not receive the treatment recommendation of the mTB and thus will undergo the standard treatment consisting of 2 cycles of chemotherapy with carboplatin AUC5 3-weekly and paclitaxel 175 mg/m2 3-weekly or carboplatin AUC2 weekly and Paclitaxel 60-80mg/m2 weekly. Either q3w regime or q1w regime.
- interventionNames
- Drug: Carboplatin / Paclitaxel Chemotherapy
- type
- EXPERIMENTAL
- label
- Interventional Arm
- description
- The intervention studied is a treatment recommendation by a specialized molecular tumorboard. This recommendation is based on an MSR which is created by TP, i.e., molecular analysis of clinical specimens, obtained from the individual participant. TP, a technology platform of several precision-cancer profiling domains, combines and rates the most efficient drugs/ experimental treatments for an individual ovarian cancer patient independent of standard of care. The usability in clinical practice of this recommendation will be tested. It should support the clinical decision of the treating oncologists and patients to choose the best possible therapy for the individual patient.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed EOC (adenocarcinoma of the ovary, peritoneum, and fallopian tube) and carcinosarcoma patients with a suspected FIGO Stage III and IV * No immediate need of systemic or surgical treatment at time of and until 2 weeks after diagnosis * Envisaged surgical candidate for interval debulking after 2 cycles of treatment * Willing and able to attend the visits, to understand the purpose of the trial and all trial-related procedures * ECOG 0-2 * Written informed consent according to national legal and regulatory requirements prior to any project specific procedures Exclusion Criteria: * Elevated liver enzymes (double of normal range: ASAT \> 68 U/l; ALAT \> 82 U/l; GGT \> 80 U/l) * Elevated creatinine (double of normal range: \>120 mmol/l)) * ECOG ≥3 * Pregnant or lactating women * Any other malignancy within the last 5 years which has an impact on the prognosis of the patient * Inability to swallow tablets * Concurrent participation in another clinical trial on the same indication * Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the sponsor-project leader may interfere with the project or affect patient compliance
References
Publications (0)
Data not yet available
No reference posted for this study.